PP-006 Adefovir resistance detection in chronic hepatitis B patients with primary non-response to adefovir treatment  by Yang, S. et al.
Poster Presentations S57
PP-006 Adefovir resistance detection in chronic
hepatitis B patients with primary non-response
to adefovir treatment
S. Yang1 *, R.X. Xue1, Q. Wang1, H.C. Xing2, J. Guo2,
W. Xie2, J. Yan2, J. Cheng1. 1Institute of Infectious
Diseases, Beijing Ditan Hospital, Beijing, China, 2Center of
Liver Diseases, Beijing Ditan Hospital, Beijing, China
Background and Objective: There is no consensus on which
kind of chronic hepatitis B (CHB) patients should undergo
drug resistance assay during adefovir treatment. The aim of
this study is to determine adefovir resistance proﬁle in CHB
patients who are primary non-response (decrease in serum
HBVDNA by <2 log10 IU/ml) to adefovir treatment.
Method: Serum samples were collected from 28 CHB
patients who were primary non-response to adefovir
treatment. HBVDNA level was assayed by Cobas Taqman
real time PCR. Nested PCR were performed and direct
sequencing of PCR products and cloning sequencing were
used to identify adefovir resistance. HBV genotype and
subgenotype were identiﬁed by phylogenetic tree analysis
of sequencing results.
Results: Serum samples from 28 patients were collected
(25 males and 3 females). Mean age was 39.54 years
(22 62 years). Mean treatment time of adefovir was
15.11 months (6 28 months). During adefovir treatment,
22/28 cases were HBeAg positive; 3/28 cases were anti-HBe
positive; 1/28 case underwent HBeAg seroconversion and
2/28 cases are both negative for HBeAg and anti-HBeAg.
Mean initial HBVDNA level was 4.70 log10 IU/ml (2.51 8.28).
6/28 patients were infected with B2 genotype HBV and
22/28 patients were with C2 genotype. Adefovir resistance
mutations were detected in 7 cases (25%): rtA181T mutation
in 5 cases; rtA181V mutation in 1 case and rtA181V plus
rtN236T mutations in 1 case. There was no difference in
initial HBVDNA level (4.61 versus 5.69, P > 0.05) between
patients with and without adefovir resistance. HBeAg status
and HBV genotype were not related to adefovir resistance
(both P > 0.05). HBVDNA level decrease (log10 IU/ml)/month
was different between patients with adefovir resistance and
without (0.0195 versus 0.0298, P< 0.05). Especially, there is
no difference in adefovir resistance rate between patients
who are non-response after 6 12 months treatments (3/12)
and patients after >12 months treatments (4/16).
Conclusion: Patients who are non-response to adefovir
treatment may be caused by adefovir resistance mutations,
mainly rtA181T. Adefovir resistance patients had less
HBVDNA decrease per month. And adefovir resistance
mutation may occur after 6 12 months adefovir treatment
as they do after >12 months treatments. Thus adefovir
resistance assay is indicated in patients who are primary
non-response to adefovir after 6 months treatment;
especially in patients who had less HBVDNA decrease.
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Background and Objective: To analyze the adefovir
resistance proﬁle in Chinese chronic hepatitis B (CHB)
patients with viral breakthrough during adefovir treatment
and the correlation between HBV genotype and adefovir
resistance.
Method: Serum samples were collected from CHB
patients who underwent viral breakthrough during adefovir
treatment. HBVDNA level was assayed by Cobas Taqman
real time PCR. Nested PCR were performed and direct
sequencing of PCR products and cloning sequencing were
used to identify adefovir resistance. HBV genotype and
subgenotype were identiﬁed by phylogenetic tree analysis
of sequencing results.
Results: Serum samples from 55 patients were collected
(41 males and 14 females). Mean age was 39.69 years
(17 64 years). Mean treatment time of adefovir before
viral breakthrough was 19.11 months (5 36 months) and
mean HBVDNA level between adefovir treatment was
5.51 log10 copies/ml (3.01 7.32). 49/55 cases were HBeAg
positive and 6/55 cases were anti-HBe positive. 13 cases
were infected with genotype B2 HBV and 42 cases with
genotype C2. Adefovir resistance was detected in 19/55
cases (34.55%): 5 cases with rtA181T mutation; 3 cases with
rtA181T+rtN236T mutations; 8 cases with rtA181V mutation;
1 case with rtA181V+rtN236T mutations and 3 cases with
rtN236T mutation. There are no differences in treatment
time (22.15 months versus 17.51 months, P > 0.05) and initial
HBVDNA level (5.39 versus 5.56, P > 0.05) between patients
with adefovir resistance mutations and without mutations.
There is no difference in adefovir resistance between
HBeAg positive and negative patients (16/49 versus 3/6,
P > 0.05). Also there is no difference in adefovir resistance
between genotype B2 group and C2 group (3/13 versus
16/42, P > 0.05). Especially, the rtA181T mutation in all
7 cases had sW172stop mutation in the overlapping HBsAg
protein, which results in truncation of HBsAg. And 6/7 cases
had increase in HBVDNA level of 1 2 log10 copies/ml over
6 months. But 1/7 cases had increase of 4.27 log10 copies/ml
over 12 months which is different from previous reports.
Conclusion: There are no differences in adefovir resistance
between HBV genotype B2 and HBV genotype C2 and
between HBeAg positive and anti-HBe Positive patients in
Chinese. And we ﬁnd one rtA181T mutation patient with
HBVDNA level increase of 4.27 log10 copies/ml.
PP-008 Quantiﬁcation of hepatitis B virus total DNA and
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hepatitis B patients’ serum and liver biopsies
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Aim: To quantify hepatitis B virus (HBV) total DNA and
covalently closed circular DNA (cccDNA) in liver biopsies and
sera which from cirrhosis patient caused by HBV infection
and research their application in clinical.
Methods: Total HBVDNA and cccDNA in serum and in liver
biopsy samples were measured in 60 liver cirrhosis patients
by the real-time PCR assay. ALT, TBIL were measured by
ELISA.
Results: 59 out of 60 (98.3%) total HBVDNA was positive in
serum and liver biopsy samples. CccDNA was all negative
in serum samples.24 out of 60 (40%) cccDNA was positive
in liver biopsy samples, positive proportion in 9 HBeAg-
positive, 17 HBeAg-negative anti-HBe- negative, 34 anti-
HBe- positive was 66.7%, 52.9% and 26.5%, respectively.
The levels of total HBVDNA, cccDNA in liver biopsy samples
and total HBVDNA in serum samples decreased progressively
in the above three groups, moreover HBeAg-positive group
had signiﬁcantly higher levels than the anti-HBe- positive
group (log [total serum HBVDNA] P= 0.032; log [total
intrahepatic HBVDNA] P= 0.004; log [intrahepatic cccDNA]
P= 0.017). Total intrahepatic HBVDNA correlated well with
intrahepatic cccDNA (r = 0.534, P< 0.01) and total HBVDNA in
serum samples (r = 0.885, P< 0.01). No correlation between
Total HBVDNA in serum samples and intrahepatic cccDNA
(r = 0.177, P= 0.177). Intrahepatic total HBVDNA, cccDNA
and total HBVDNA in serum samples had no correlation with
ALT, TBIL.
